NASDAQ:QTRX - Quanterix Stock Price, Forecast & News

Quanterix's stock was trading at $18.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, QTRX stock has decreased by 7.8% and is now trading at $17.07. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Quanterix.

Quanterix is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Quanterix.

2 brokers have issued 1 year price targets for Quanterix's stock. Their forecasts range from $32.00 to $35.00. On average, they anticipate Quanterix's stock price to reach $33.50 in the next year. This suggests a possible upside of 96.3% from the stock's current price. View analysts' price targets for Quanterix.

Press coverage about QTRX stock has trended very positive on Saturday, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quanterix earned a coverage optimism score of 3.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutQuanterix.

Quanterix saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,439,700 shares, an increase of 16.1% from the February 27th total of 1,240,000 shares. Based on an average trading volume of 161,200 shares, the short-interest ratio is currently 8.9 days. Approximately 7.4% of the shares of the stock are sold short. View Quanterix's Current Options Chain.

Some companies that are related to Quanterix include Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Arrayit (ARYC), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include InVitae (NVTA), Allena Pharmaceuticals (ALNA), Crispr Therapeutics (CRSP), Spero Therapeutics (SPRO), Veracyte (VCYT), KeyCorp (KEY), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), Ardelyx (ARDX) and Cara Therapeutics (CARA).

(QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Quanterix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Macquarie Group Ltd. (4.78%), Macquarie Group Ltd. (4.74%), FMR LLC (3.17%), Royce & Associates LP (1.86%), State Street Corp (0.86%) and Bank of New York Mellon Corp (0.74%). Company insiders that own Quanterix stock include David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Martin D Madaus. View institutional ownership trends for Quanterix.

QTRX stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Barclays PLC, Credit Suisse AG, Bank of America Corp DE, Advisory Research Inc., AQR Capital Management LLC, Carnegie Capital Asset Management LLC, and Geode Capital Management LLC. Company insiders that have sold Quanterix company stock in the last year include David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, Marijn E Dekkers, Mark T Roskey, and Martin D Madaus. View insider buying and selling activity for Quanterix.

QTRX stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Macquarie Group Ltd., FMR LLC, Kornitzer Capital Management Inc. KS, Bank of Montreal Can, State Street Corp, Platinum Investment Management Ltd., and Renaissance Technologies LLC. Company insiders that have bought Quanterix stock in the last two years include David R Walt, and John M Connolly. View insider buying and selling activity for Quanterix.

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of QTRX stock can currently be purchased for approximately $17.07.

Quanterix has a market capitalization of $481.89 million and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Quanterix employs 177 workers across the globe. View additional information about Quanterix.

The official website for Quanterix is http://www.quanterix.com/.

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400.